Company

Neumirna Therapeutics ApS

Neumirna Therapeutics develops RNA therapies for neurological disorders.

About

Founded in 2020 and based in Copenhagen, Neumirna Therapeutics develops RNA therapies for neurological disorders, including epilepsy. Its lead product, NMT.001, targets molecular pathways involved in these conditions. In January 2025, it raised EUR 20 million in Series A funding co-led by Angelini Ventures and Invivo Partners, with Innovestor participating. CEO Janine Erler led the company as of that month.

1Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in